NT-proBNP

There are 657 papers on NT-proBNP in aging research: 94 trials and 476 observational studies in people, 13 in animals, 51 reviews. The newest story, Nov 16, 2026: “Loss of nuclear support proteins harms mouse hearts and arteries”.

Biomarker

657 papers study it88 more mention it324 findings

159 new papers in 30 daysSee all 745 papers on NT-proBNP

At a glance

Human cohorts link higher NT-proBNP with mortality and lower grip strength, and with incident frailty in people without known cardiovascular disease at baseline. A human trial reports decreases with empagliflozin in heart failure with reduced ejection fraction and diabetes or prediabetes, while another shows no clear effect with cholecalciferol in older adults with low vitamin D levels.

324 findings in 250 papers from 2007 to 2026, 95 of them since April 2026

“those with lower Ca2+ (Q1, mean 2.2 ± 0.1 mmol/L) presented more peripheral edema and higher NT-proBNP levels (P < 0.05).”
Impact of Empagliflozin on Serum Calcium and Phosphate in Heart FailureJournal of cardiac failure2026doi:10.1016/j.cardfail.2026.07.026
  • Human trial94
  • Humans476
  • Animals13
  • In silico8

Interventions

44

SGLT2 inhibitors

downin humans8no changein humans2

10 studies
  1. SGLT2 inhibitors decrease NT-proBNP in humans (Persistent atrial fibrillation with heart failure undergoing catheter ablation).

    “SGLT2i[+] had significantly lower NT-proBNP levels at 1 month than SGLT2i[-].”

    Human trialPersistent atrial fibrillation with heart failure undergoing catheter ablation1 monthn = 200

    Sodium-Glucose Cotransporter-2 Inhibitors Increase Estimated Glomerular Filtration Rate Slope and Ameliorate Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients with Heart Failure

    AHA Scientific Sessions 2026 abstract

  2. SGLT2 inhibitors decrease NT-proBNP in humans (post-ACS diabetic patients, SGLT2i group vs control, at 3 months) (5541.6±8443.5 to 1179.6±1644.6 pg/ml).

    “NT-proBNP decreased markedly in the SGLT2i group (5541.6±8443.5 to 1179.6±1644.6 pg/ml, p=0.004)”

    Human trialpost-ACS diabetic patients, SGLT2i group vs control, at 3 months3 monthsn = 25

    Effect of SGLT2 inhibitors on left atrial strain in patients of acute coronary syndrome and diabetes mellitus

    ESC Congress 2026 abstract

  3. SGLT2 inhibitors decrease NT-proBNP in humans (HFpEF; before-and-after comparison without a control group) (Median 176.5 pg/mL vs 683 pg/mL at baseline; p ≤0.001).

    “After six months, the NT-proBNP levels significantly decreased”

    Human trialHFpEF; before-and-after comparison without a control group10 mg/day6 months82% femalesn = 100

    Role of SGLT2I in improving right ventricular systolic function in patients with HFpEF

    ESC Congress 2026 abstract

  4. SGLT2 inhibitors decrease NT-proBNP in humans (HFpEF and diabetes mellitus; added to standard care).

    “along with reductions in CRP and NT-proBNP.”

    Human trialHFpEF and diabetes mellitus; added to standard care6 months62% malesn = 32

    Myocardial extracellular volume reduction is associated with improved cardiac function after SGLT2 inhibitor therapy in HFpEF

    Scientific reports

  5. SGLT2 inhibitors decrease NT-proBNP in humans (1,687.0 ± 897.8 to 1,212.6 ± 606.6 pg/mL).

    “The mean serum NT-proBNP level decreased significantly from 1,687.0 ± 897.8 pg/mL at baseline to 1,212.6 ± 606.6 pg/mL at follow-up (p < 0.001).”

    Human trialChronic rheumatic heart disease and NYHA class II-IV heart failure; added to standard heart failure therapyserum3 monthsn = 90

    Clinical and Biochemical Responses to SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors in Patients With Rheumatic Heart Disease and Heart Failure

    Cureus

  6. SGLT2 inhibitors were not clearly linked with NT-proBNP in humans (Fontan circulation; within-cohort change from baseline).

    “while remaining stable in the SGLT2i cohort (p=0.766; Fig C )”

    HumansFontan circulation; within-cohort change from baseline6 monthsn = 10

    Baseline Characteristics and Interim Analysis of the DEFEND Study: SGLT2 Inhibition in Patients with a Fontan

    AHA Scientific Sessions 2026 abstract

  7. SGLT2 inhibitors are linked with lower NT-proBNP in humans (compared with non-SGLT2i users) (p<0.05).

    “while MR-proADM, PINP, and NT-proBNP were lower (p<0.05) in SGLT2i users”

    Humanscompared with non-SGLT2i usersplasma

    SGLT2 inhibitors and molecular signatures of aortic valve remodeling in severe aortic stenosis: the Valve-AS study

    ESC Congress 2026 abstract

  8. SGLT2 inhibitors are linked with lower NT-proBNP in humans (patients with cardiac amyloidosis (AL and ATTR)) (MD –464.68 pg/mL; 95% CI –712.22 to –217.15).

    “NT-proBNP levels (MD: –464.68 pg/mL; 95% CI –712.22 to –217.15; p = 0.0002)”

    Humanspatients with cardiac amyloidosis (AL and ATTR)

    SGLT2 Inhibitors Reduce Mortality and Improve Cardiac Biomarkers in Cardiac Amyloidosis: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2025 abstract

  9. SGLT2 inhibitors decrease NT-proBNP in humans after AF catheter ablation (SMD –0.59, 95% CI –0.88 to –0.29).

    “SGLT2 inhibitors significantly lowered NT-proBNP levels (SMD –0.59, 95% CI –0.88 to –0.29; P<0.001)”

    Reviewafter AF catheter ablation

    SGLT2 Inhibitors After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials with Reconstructed Kaplan-Meier Data

    AHA Scientific Sessions 2026 abstract

  10. SGLT2 inhibitors showed no clear effect on NT-proBNP in humans (moderate or severe complexity ACHD) (mean difference -240 pg/mL [-516,45]).

    “there was no significant post therapy change in NT-proBNP or BNP (mean difference -240 pg/mL [-516,45] and -52 pg/mL [-129,26], respectively)”

    Reviewmoderate or severe complexity ACHDn = 174

    Sodium glucose co-transport inhibitors to treat heart failure in patients with complex adult congenital heart disease - a systematic review and meta-analysis

    medRxivPreprint

More on SGLT2 inhibitors

Dapagliflozin

downin humans6no changein humans1upin humans1

8 studies
  1. Dapagliflozin decreases NT-proBNP in humans (Hospitalized acute heart failure; compared with acetazolamide alongside standard care) (−34.2% vs. −25.0%; P = 0.003).

    “Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003).”

    Human trialHospitalized acute heart failure; compared with acetazolamide alongside standard care10 mg once daily72 hoursn = 108

    Acetazolamide eased breathlessness more in acute heart failure

    Clinical pharmacology and therapeutics

  2. Dapagliflozin showed no clear effect on NT-proBNP in humans (Stable PAH or CTEPH; compared with placebo) (Interaction p=0.39).

    “or NT-proBNP trajectory through week 4 and 12 (mixed model, interaction p=0.39).”

    Human trialStable PAH or CTEPH; compared with placebo10 mg daily4 and 12 weeksn = 52

    Dapagliflozin did not clearly improve exercise capacity

    ESC Congress 2026 abstract

  3. Dapagliflozin increases NT-proBNP in humans (type 2 diabetes without heart failure, on metformin monotherapy at recruitment) (+20% from baseline; p=0.07).

    “whereas it increased by 20% in the dapagliflozin group (p=0.07).”

    Human trialtype 2 diabetes without heart failure, on metformin monotherapy at recruitmentplasma6 monthsn = 92

    Effects of semaglutide and dapagliflozin on natriuretic peptides in type 2 diabetes: a randomized comparative study

    ESC Congress 2026 abstract

  4. Dapagliflozin decreases NT-proBNP in humans (-142 pg/mL (95% CI -324 to 41)).

    “The estimated intervention-versus-baseline difference was −142 pg/mL (95% CI −324–41) for NT-proBNP, 24.3 m (95% CI −2.8 to 51.5) for 6MWT distance, and 0.4 points (95% CI −4.0 to 4.8) for KCCQ-TSS.”

    Human trial12 weeksn = 7

    Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study

    PloS one

  5. Dapagliflozin decreases NT-proBNP in patients with HFrEF combined with T2DM.

    “while their fasting plasma glucose, 2-h postprandial glucose, glycosylated hemoglobin, insulin resistance index, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, cardiac troponin I, creatine kinase-MB, N-terminal pro b-type natriuretic peptide, serum creatinine, and blood urea nitrogen were significantly lower”

    Human trialin patients with HFrEF combined with T2DM

    Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

    World journal of diabetes

  6. Dapagliflozin is linked with lower NT-proBNP in humans (28.4% reduction versus 8.7% reduction in controls).

    “NT-proBNP levels in the SGLT-2 inhibitor group exhibited a substantial 28.4% reduction”

    HumansHFpEF; combined with standard guideline-directed therapy versus standard guideline-directed therapy alone6 monthsn = 58

    SGLT-2 inhibitor dapagliflozin improves left ventricular diastolic function and reduces circulating inflammatory markers in HFpEF patients: a retrospective cohort study

    American journal of translational research

  7. Dapagliflozin is linked with lower NT-proBNP in humans during doxorubicin therapy in breast cancer patients with type 2 diabetes (+57.000 [95% CI +28.302, +85.698]).

    “lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001)”

    Humansduring doxorubicin therapy in breast cancer patients with type 2 diabetes3 monthsn = 60

    Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study

    BMC cancer

  8. Dapagliflozin is linked with lower NT-proBNP in humans (heart failure with preserved ejection fraction) (p = 0.046 and p = 0.039).

    “NT-proBNP and BNP levels showed significantly greater reductions in the dapagliflozin group (p = 0.046 and p = 0.039, respectively).”

    Humansheart failure with preserved ejection fractionn = 215

    Efficacy and Safety of Dapagliflozin in Patients Over 75 Years Old With Heart Failure With Preserved Ejection Fraction: A Retrospective Study

    British journal of hospital medicine (London, England : 2005)

More on Dapagliflozin

Empagliflozin

downin humans3upin humans1

4 studies
  1. Empagliflozin decreases NT-proBNP in humans (Heart failure with reduced ejection fraction and type 2 diabetes or prediabetes).

    “Across the overall study population, uric acid and NT-proBNP decreased and haematocrit increased”

    Human trialHeart failure with reduced ejection fraction and type 2 diabetes or prediabetes36 weeksn = 105

    Empagliflozin reduced heart chamber volumes alongside other drugs

    ESC Congress 2026 abstract

  2. Empagliflozin decreases NT-proBNP in humans.

    “Notably, there were significant improvements in GNRI (p < 0.001), MNA (p < 0.001), KCCQ12-OS (p < 0.01), KCCQ12-CS (p < 0.01), BMI (p = 0.005), and NT-proBNP (p < 0.001).”

    Human trial6 monthsn = 93

    Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure

    BMC cardiovascular disorders

  3. Empagliflozin is linked with better NT-proBNP in humans (heart failure, with or without diabetes).

    “and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (p < 0.001).”

    Humansheart failure, with or without diabetes10 mg dailysix monthsn = 797

    Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh

    BMC endocrine disorders

  4. Empagliflozin is linked with lower NT-proBNP in humans (type 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulin) (1699 ± 522 vs. 2303 ± 598 pg/ml at discharge).

    “the N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were lower in the empagliflozin continuation group than in the insulin group”

    Humanstype 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulincombined with basal insulin regimenduring hospitalization

    Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

    Journal of the American Geriatrics Society

More on Empagliflozin

Sacubitril + valsartan

downin humans3

3 studies
  1. Sacubitril + valsartan decreases NT-proBNP in humans after switching from azilsartan (-18.3 ± 25.5%).

    “Sacubitril/valsartan treatment decreased BP, morning‐to‐nighttime decrease in home SBP, body mass index, body weight, and NT‐proBNP level, whereas other variables such as potassium and estimated glomerular filtration rate did not change significantly.”

    Human trialafter switching from azilsartan6 monthsn = 27

    Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring

    Journal of clinical hypertension (Greenwich, Conn.)

  2. Sacubitril + valsartan decreases NT-proBNP in humans after switching from azilsartan (188.2 [85.3-887.3] to 124.0 [83.6-696.2] pg/mL).

    “median (IQR) NT-proBNP level (188.2 [85.3-887.3] to 124.0 [83.6-696.2] pg/mL) were observed.”

    Human trialafter switching from azilsartan170±47 mg/day6 monthsn = 27

    Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring

    Journal of clinical hypertension (Greenwich, Conn.)

  3. Sacubitril + valsartan decreases NT-proBNP in humans (heart failure with reduced ejection fraction).

    “we observed a significant improvement in humoral and functional parameters of CGA, renal function, NTpro-BNP levels and echocardiographic parameters.”

    Human trialheart failure with reduced ejection fraction6 monthsn = 61

    Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis

    Internal and emergency medicine

  4. Sacubitril + valsartan is linked with lower NT-proBNP in humans (post-acute myocardial infarction heart failure; compared with enalapril).

    “The sacubitril/valsartan group had bigger decreases in NT-proBNP (P < 0.001) and cTnI (P = 0.030).”

    Humanspost-acute myocardial infarction heart failure; compared with enalaprilone yearn = 204

    Impact of sacubitril/valsartan on cardiac structure and function in post-acute myocardial infarction heart failure patients aged over 65: a single-center experience

    American journal of translational research

More on Sacubitril + valsartan

Nicotinamide adenine dinucleotide

downin humans1no changein humans1

2 studies
  1. Nicotinamide adenine dinucleotide decreases NT-proBNP in humans (STEMI following primary PCI; 7 days of treatment versus placebo).

    “NT-proBNP levels were lower in the NAD+ group at follow-up.”

    Human trialSTEMI following primary PCI; 7 days of treatment versus placebo10 mg/dayfollow-upn = 120

    Effect of Intravenous Nicotinamide Adenine Dinucleotide on Left Ventricular Function After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial

    American journal of cardiovascular drugs : drugs, devices, and other interventions

  2. Nicotinamide adenine dinucleotide showed no clear effect on NT-proBNP in humans (1471.00 [828.00–2950.00]pg/mL vs. 2317.50 [1155.00–4752.50]pg/mL).

    “As presented in Table, there was a trend towards reduced levels of NT-proBNP in the NAD+ group at 7 days (1471.00 [828.00–2950.00]pg/mL vs. 2317.50 [1155.00–4752.50]pg/mL, p = 0.102].”

    Human trial7 consecutive daysn = 180

    Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial

    American journal of cardiovascular drugs : drugs, devices, and other interventions

More on Nicotinamide adenine dinucleotide

Semaglutide

downin humans2−7% from baselineRR 0.81

2 studies
  1. Semaglutide decreases NT-proBNP in humans (type 2 diabetes without heart failure, on metformin monotherapy at recruitment) (-7% from baseline).

    “During the 6-month follow-up, NT-proBNP declined significantly by 7% in the semaglutide group (p=0.01)”

    Human trialtype 2 diabetes without heart failure, on metformin monotherapy at recruitmentplasma6 monthsn = 75

    Effects of semaglutide and dapagliflozin on natriuretic peptides in type 2 diabetes: a randomized comparative study

    ESC Congress 2026 abstract

  2. Semaglutide decreases NT-proBNP in humans (patients with heart failure, pooled from RCTs and cohort studies) (RR 0.81; 95%CI 0.74 to 0.89).

    “NT-proBNP (RR:0.81; 95%CI: 0.74 to 0.89; p<0.00001)”

    Human trialpatients with heart failure, pooled from RCTs and cohort studies

    Semaglutide as an effective therapy for heart failure: Evidence from a meta-analysis of 6,479 patients

    AHA Scientific Sessions 2025 abstract

More on Semaglutide

Tirzepatide

downin humans2

2 studies
  1. Tirzepatide is linked with lower NT-proBNP in humans (heart failure, HFrEF or HFpEF) (2200 ± 750 pg/mL to 1400 ± 620 pg/mL).

    “and NT-proBNP levels (2200 ± 750 pg/mL to 1400 ± 620 pg/mL, p < 0.001)”

    Humansheart failure, HFrEF or HFpEFsix monthsn = 100

    Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure

    Cureus

  2. Tirzepatide decreases NT-proBNP in humans (Compared with placebo or standard of care; three studies) (-17.6% (95% CI -26.7% to -8.5%)).

    “and NT-proBNP by 17.6% (95% CI: -26.7% to -8.5%; P = .0001; I2 = 58.1%; 3 studies).”

    ReviewCompared with placebo or standard of care; three studies

    Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis

    The Journal of clinical endocrinology and metabolism

More on Tirzepatide

Exercise

downin humans2

2 studies
  1. Exercise decreases NT-proBNP in frail patients undergoing coronary artery bypass grafting.

    “as well as a decrease in NT-proBNP ( p = 0.009) and ST2 ( p = 0.002) levels.”

    Human trialin frail patients undergoing coronary artery bypass graftingtreadmill training14-18 daysn = 36

    Effects of Early Rehabilitation in Patients with Frailty Syndrome Undergoing Coronary Artery Bypass Grafting

    Bulletin of Siberian Medicine

  2. Exercise decreases NT-proBNP in humans (chronic heart failure).

    “after the intervention, NT-proBNP levels and MLHFQ scores in the rehabilitation group were both lower than before the intervention and lower than those in the control group (P<0.05)”

    Human trialchronic heart failure3 monthsn = 92

    Effect of Exercise Rehabilitation Therapy on Cardiopulmonary Function, Cardiac Pumping Function, NT-proBNP, and Quality of Life in Elderly Patients with Chronic Heart Failure

    Chinese Health Care

More on Exercise

Coenzyme Q10 + selenium

downin humans2

2 studies
  1. Coenzyme Q10 + selenium decreases NT-proBNP in humans.

    “Equally, in the male group at 48 months, a higher value in the placebo group compared with the active treatment group was noted (F(1,98)= 4.20; p = 0.04).”

    Human trialfour-year

    Selenium and Coenzyme Q₁₀ Supplementation and Sex Differences in Cardiovascular Mortality Results from a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly People Low in Selenium

    Antioxidants (Basel, Switzerland)

  2. Coenzyme Q10 + selenium decreases NT-proBNP in humans (214 ng/L vs. 302 ng/L at 48 months (P=0.014)).

    “NT-proBNP levels were significantly lower in the active group compared with the placebo group (mean values: 214 ng/L vs. 302 ng/L at 48 months; P=0.014).”

    Human trial48 monthsn = 443

    Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens

    International journal of cardiology

More on Coenzyme Q10 + selenium

Plant-based meat-supplemented diet

upin humans1

1 study
  1. Plant-based meat-supplemented diet increases NT-proBNP in humans (+ 0.19log units, 95%CI + 0.04 to + 0.35).

    “The plant-based sequence was associated with significant increase in weight (+ 0.6 kg, 95%CI + 0.1 to + 1.0, P = 0.012); and NTproBNP (57 (27–148)pg/mL vs 54 (16–106)pg/mL, + 0.19log units, 95%CI + 0.04 to + 0.35; P = 0.013).”

    Human trial6 daysn = 41

    Processed plant-based meat-supplemented diet versus red meat-based supplemented diet randomized cross-over trial Finding Optimal Oral Diet-1 (FOOD-1) trial

    Scientific reports

  2. Plant-based meat-supplemented diet increases NT-proBNP in humans (randomized cross-over trial) (+ 0.19 log units (95%CI + 0.04 to + 0.35)).

    “NTproBNP: + 0.19 log units (95%CI + 0.04 to + 0.35)”

    Human trialrandomized cross-over trial6 daysn = 41

    Processed plant-based meat-supplemented diet versus red meat-based supplemented diet randomized cross-over trial Finding Optimal Oral Diet-1 (FOOD-1) trial

    Scientific reports

More on Plant-based meat-supplemented diet

Hypercaloric, hyperproteic oral supplement

downin humans1

1 study
  1. Hypercaloric, hyperproteic oral supplement decreases NT-proBNP in humans (plus Mediterranean diet) (decreased by 1303 pg/mL (741–2111) after 24 weeks).

    “In particular, the intervention group (1952 pg/mL (1179–3307 at baseline) decreased by 1303 pg/mL (741–2111) after 24 weeks (p = 0.02). Although NT-proBNP also decreased in the control group, this change was not statistically significant.”

    Human trialplus Mediterranean diettwenty-four weeksn = 19

    Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure-A Randomized Clinical Trial

    Nutrients

  2. Hypercaloric, hyperproteic oral supplement decreases NT-proBNP in patients with heart failure.

    “Serum values of NT-proBNP also significantly decreased in the whole cohort (p < 0.01), especially in the intervention group (p = 0.02)”

    Human trialin patients with heart failure24 weeksn = 38

    Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure-A Randomized Clinical Trial

    Nutrients

More on Hypercaloric, hyperproteic oral supplement

Sauna bathing

upin humans1+12%

1 study
  1. Sauna bathing increases NT-proBNP in humans (+12.00%).

    “Overall NT-proBNP levels were 46.0 ng/L before sauna exposure, which increased to 50.5 ng/L immediately after sauna (median percentage change, 12.00%; p < 0.001).”

    Human trialplasma30 minn = 102

    Short-term effects of Finnish sauna bathing on blood-based markers of cardiovascular function in non-naive sauna users

    Heart and vessels

  2. Sauna bathing increases NT-proBNP in humans (+12.00%, p < 0.001).

    “Overall median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level (n = 20 participants) was 46.0 ng/L before sauna exposure, which increased to 50.5 ng/l immediately after sauna (median change, + 12.00%; p < 0.001)”

    Human trial30-minn = 20

    Short-term effects of Finnish sauna bathing on blood-based markers of cardiovascular function in non-naive sauna users

    Heart and vessels

More on Sauna bathing

Zero-time exercise

downin humans1

1 study
  1. Zero-time exercise decreases NT-proBNP in humans (clinically stable heart failure with reduced ejection fraction) (Median 1260.5 versus 1533.9 pg/mL; P = .005).

    “lower NT-proBNP (median, 1260.5 vs 1533.9 pg/mL; P = .005)”

    Human trialclinically stable heart failure with reduced ejection fraction8 weeksn = 78

    A Nurse-Led, Daily Routine-Integrated Exercise Intervention for Older Adults with Heart Failure and Reduced Ejection Fraction: An Exploratory Randomized Controlled Trial

    Frontiers in medicine

More on Zero-time exercise

Intensive blood pressure control

upin humans1

1 study
  1. Intensive blood pressure control increases NT-proBNP in humans (Type 2 diabetes; compared with standard blood pressure control).

    “Compared with standard BP control, intensive BP control increased NT-proBNP over 1- and 4-year follow-up”

    Human trialType 2 diabetes; compared with standard blood pressure controlSystolic BP target <120 mmHg versus <140 mmHg1 and 4 years

    Heart markers flagged risk, not benefit from tighter pressure control

    AHA Scientific Sessions 2026 abstract

More on Intensive blood pressure control

Exenatide

downin humans1

1 study
  1. Exenatide decreases NT-proBNP in humans (type 2 diabetes; compared with placebo).

    “Proteins that decreased more with EQW vs. placebo (n=320) included tenascin, NT-proBNP”

    Human trialtype 2 diabetes; compared with placeboonce-weekly12 monthsn = 3,973

    Diabetes drug altered proteins linked to heart risk

    AHA Scientific Sessions 2026 abstract

More on Exenatide

All 44

Effects

19

Mortality

no changein humans2HR 1

2 studies
  1. NT-proBNP was not clearly linked with mortality in humans (NT-proBNP concentration above 1099 ng/L).

    “When the NT-proBNP concentration was above 1099 ng/L, the mortality did not increase anymore when NT-proBNP increased (OR=1.00, 95%CI: 0.99-1.02, P=0. 7786).”

    HumansNT-proBNP concentration above 1099 ng/L

    The Predictive Value of Serum NT-proBNP on One-Year All-Cause Mortality in Geriatrics Hip Fracture: A Cohort Study

    Cureus

  2. NT-proBNP was not clearly linked with mortality in humans (geriatric hip fracture, preoperative NT-proBNP > 781 ng/L) (HR 1.00, 95% CI 0.98-1.01, P = 0.4718).

    “whereas at > 781 ng/L, NT-proBNP was not associated with mortality (HR = 1.00, 95% CI: 0.98-1.01, P = 0.4718).”

    Humansgeriatric hip fracture, preoperative NT-proBNP > 781 ng/Lserumn = 1,354

    The serum NT-proBNP is associated with all-cause mortality in geriatric hip fracture: a cohort of 1354 patients

    Archives of osteoporosis

Atrial fibrillation

mediatesin humans1

1 study
  1. NT-proBNP is linked with atrial fibrillation in humans.

    “Conversely, NT-proBNP mediated the relationship between increased left atrial minimum volume and AF.”

    HumansMediation of the relationship between increased left atrial minimum volume and incident atrial fibrillation in hypertensionn = 1,954

    Proteomic Signatures for predicting atrial fibrillation in hypertensive population

    Frontiers in cardiovascular medicine

More on Atrial fibrillation

SCORE2 discrimination

upin humans1

1 study
  1. NT-proBNP is linked with better SCORE2 discrimination in humans (Addition to SCORE2) (C-index 0.748 (95% CI 0.729–0.766) to 0.780 (95% CI 0.762–0.798)).

    “Addition of NT-proBNP increased discrimination to 0.780 (95% CI 0.762–0.798)”

    HumansAddition to SCORE2n = 27,450

    Incremental value of cardiac biomarkers and cancer-related factors beyond SCORE2 for prediction of cardiovascular events

    ESC Congress 2026 abstract

Muscle mass

no changein humans1

1 study
  1. NT-proBNP was not clearly linked with muscle mass in humans (multivariable adjusted).

    “whereas no significant association was observed with muscle thickness”

    Humansmultivariable adjustedn = 3,106

    Association of N-terminal pro-B-type natriuretic peptide levels with muscle quality and physical function in community-dwelling older adults: the Shizuoka study

    ESC Congress 2026 abstract

Sarcopenia

no changein humans1OR 1.45

1 study
  1. NT-proBNP was not clearly linked with sarcopenia in humans (high NT-proBNP levels; community-dwelling older adults) (OR 1.45 (95% CI 0.53-4.01) for sarcopenia).

    “high NT-proBNP levels were not significantly associated with low SMI (OR: 1.34, 95% CI: 0.54-3.32), handgrip strength (OR: 1.32, 95% CI: 0.65-2.34), or sarcopenia (OR: 1.45, 95% CI: 0.53-4.01).”

    Humanshigh NT-proBNP levels; community-dwelling older adultsn = 2,793

    High N-Terminal Pro-B-Type Natriuretic Peptide Levels Are Associated With Lower Physical Function Independent of Sarcopenia in Community-Dwelling Older Adults: The Shizuoka Study

    Geriatrics & gerontology international

More on Sarcopenia

Symptomatic alleviation

downin humans1

1 study
  1. NT-proBNP is linked with lower symptomatic alleviation in humans after T-TEER for tricuspid regurgitation (adjusted OR per log10 increase: 0.63; 95% CI: 0.48-0.84; P < 0.001).

    “higher NT-proBNP was associated with a lower likelihood of symptomatic alleviation (adjusted OR per log10 increase: 0.63; 95% CI: 0.48-0.84; P < 0.001).”

    Humansafter T-TEER for tricuspid regurgitationn = 2,282

    Prognostic Value of NT-proBNP in Patients Undergoing Tricuspid Valve Transcatheter Edge-to-Edge Repair: The EuroTR Registry

    JACC. Cardiovascular interventions

Heart failure diagnosis

upin humans1

1 study
  1. NT-proBNP improves heart failure diagnosis in humans.

    “biomarkers, particularly natriuretic peptides such as N-terminal prohormone of BNP (NT-proBNP), are central to early HF detection, showing high sensitivity.”

    Review

    Improvement initiatives in the diagnostic process of heart failure: a scoping review

    Frontiers in cardiovascular medicine

ΔLVEF below 11%

no changein humans1

1 study
  1. NT-proBNP showed no clear effect on ΔLVEF below 11% in humans (baseline levels, after 26 weeks of empagliflozin treatment).

    “baseline NT-proBNP levels did not significantly predict an unfavorable outcome after 26-weeks of empagliflozin treatment”

    Human trialbaseline levels, after 26 weeks of empagliflozin treatment26 weeks

    Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction

    Cardiovascular diabetology

Dementia risk prediction

upin humans1

1 study
  1. NT-proBNP is linked with better dementia risk prediction in humans.

    “continuous PTFV1 and NT‐pro BNP level in both the categorical scale and log scale improved model fit for incident dementia in females.”

    Humans7.6 yearsfemalesn = 3,608

    Markers of left atrial cardiopathy for the prediction of dementia risk in aging adults: An analysis of Cardiovascular Health Study

    AAIC 2025 abstract

Risk prediction

upin humans1

1 study
  1. NT-proBNP improves risk prediction in humans.

    “NT-proBNP, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin T are highlighted for their potential to enhance risk prediction and clinical management.”

    Review

    Cardiovascular ageing definition: a scoping review on conceptual and operational frameworks

    European journal of preventive cardiology

All 19

Upstream

7

Testosterone-to-estradiol ratio

no changein humans1

1 study
  1. Testosterone-to-estradiol ratio was not clearly linked with NT-proBNP in humans (postmenopausal women with HFpEF; adjusted for baseline NT-proBNP) (β=0.114, P=0.212).

    “baseline T/E2 was not associated with 12-month NT-proBNP (β=0.114, P=0.212)”

    Humanspostmenopausal women with HFpEF; adjusted for baseline NT-proBNP12 monthsfemalesn = 184

    Association of Testosterone-to-Estradiol Ratio with Inflammation and Clinical Outcomes Among Postmenopausal HFpEF

    AHA Scientific Sessions 2026 abstract

More on Testosterone-to-estradiol ratio

Celiac disease

no changein humans1

1 study
  1. Celiac disease was not clearly linked with NT-proBNP in humans.

    “NT-proBNP levels did not differ significantly between individuals with and without a known CeD diagnosis (p=.069; see figure).”

    Humans

    Traditional risk factors underestimate cardiovascular risk in individuals with coeliac disease in the Trondelag Health Study (HUNT4)

    ESC Congress 2026 abstract

More on Celiac disease

Left ventricular end-diastolic wall stress

mediatesin humans1

1 study
  1. Left ventricular end-diastolic wall stress is linked with NT-proBNP in humans (without heart failure) (mediation effect: 0.0028; 95% CI: 0.0006-0.0055).

    “The association of BMI and NT-proBNP was partially mediated by DWS (mediation effect: 0.0028; 95% CI: 0.0006-0.0055) but not SWS (mediation effect: -0.0006; 95% CI: -0.0032 to 0.0015).”

    Humanswithout heart failuren = 4,444

    Body Mass Index, Left Ventricular Wall Stress, and NT-proBNP in Elderly Adults

    JACC. Advances

Chronic kidney disease

upin humans1

1 study
  1. Chronic kidney disease is linked with higher NT-proBNP in patients with chronic heart failure (p < 0.001).

    “Levels of CRP and NT-proBNP were significantly higher in the CKD group (p < 0.001).”

    Humansin patients with chronic heart failuren = 2,227

    Impact of Chronic Kidney Disease on Clinical, Laboratory, and Echocardiographic Features in Patients with Chronic Heart Failure

    Diseases (Basel, Switzerland)

More on Chronic kidney disease

Advanced age

upin humans1

1 study
  1. advanced age is linked with higher NT-proBNP in humans (undergoing mitral valve repair) (p < 0.001).

    “significantly higher plasma levels of NT-proBNP”

    Humansundergoing mitral valve repair

    Mitral Valve Repair in Advanced Age Groups: Does Cardiac Age Differ from Chronological Age?

    Journal of clinical medicine

Older age

upin humans1

1 study
  1. Older age is linked with higher NT-proBNP in individuals without previous cardiovascular disease (rising from 1.4% (<30y) to 81.0% (≥80y) in males, and 9.8% (<30y) to 76.5% (≥80y) in females).

    “At age <30 years, 9.8% of females and 1.4% of males had elevated NT-proBNP, rising to 76.5% and 81.0%, respectively, at age ≥80 years.”

    Humansin individuals without previous cardiovascular diseasen = 18,356

    Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort

    Circulation. Heart failure

Older adults

upin humans1

1 study
  1. Older adults are linked with higher NT-proBNP in humans.

    “We observed an age-dependent increment of NT-proBNP levels with higher values in women compared to men.”

    Humans

    N-terminal pro brain natriuretic peptide reference values in community-dwelling older adults

    ESC heart failure

More on Older adults

Associations

147

Mortality

upin humans28HR 1–3.9

28 studies
  1. NT-proBNP is associated with mortality in humans (HR 1.68, 95% CI 1.19–2.37).

    “high versus low NT-proBNP was associated with a 1.68-fold higher mortality hazard”

    HumansFrail cancer patients hospitalized with established anticancer treatment-related cardiac dysfunction/heart failure; high versus low NT-proBNP using cohort median 4562 pg/mLMedian follow-up 28 monthsn = 399

    Combined RDW-CV and NT-proBNP for all-cause mortality prognostication in frail older cancer patients hospitalized with anticancer treatment-related cardiac dysfunction: a retrospective cohort study

    Frontiers in cardiovascular medicine

  2. NT-proBNP is associated with mortality in humans (36.4% vs 5.3%).

    “gray zone NT-proBNP values were associated with higher long-term risks of HF hospitalization and all-cause mortality compared with rule-out values.”

    Humansmedian follow-up of 2.7 yearsn = 454

    Gray zone NT-proBNP values and long-term outcomes in emergency department patients without prior heart failure

    Revista espanola de cardiologia (English ed.)

  3. NT-proBNP is linked with a higher risk of mortality in humans (heart failure) (HR 1.76, 95% CI 1.30-2.38).

    “high NT-proBNP (HR:1.76; 95%CI 1.30-2.38) and HF readmissions within 1 year (HR:2.68; 95%CI 1.72-4.16) remained independently associated with mortality.”

    Humansheart failuren = 514

    Half of patients 85-plus at one heart failure unit lived 2.5 years

    Geriatrics (Basel, Switzerland)

  4. NT-proBNP is associated with mortality in humans (increasing NT-proBNP (change ≥+25%) compared with no change) (HR 1.73 (95% CI 1.37-2.17)).

    “multivariable-adjusted HRs in the increasing group were 1.73 (95% CI 1.37-2.17), 1.76 (95% CI 1.08-2.87), and 1.71 (95% CI 1.32-2.22) for all-cause, cardiovascular, and non-cardiovascular mortality”

    Humansincreasing NT-proBNP (change ≥+25%) compared with no changeserum10.3 yearsn = 2,703

    Association Between Changes in Serum N-Terminal Pro B-Type Natriuretic Peptide Levels and All-Cause and Cause-Specific Mortality - The Hisayama Study

    Circulation journal : official journal of the Japanese Circulation Society

  5. NT-proBNP predicts mortality in humans (HR 1.31 per 1 SD).

    “NT-proBNP (hazard ratio [HR] per 1 SD 1.31), HbA1c (1.24) and albumin (0.81) carried most of the signal”

    Humansper 1 SDmedian 4.4 yearsn = 2,144

    Seven routine blood markers predict five-year mortality in older Indians: a risk score from the LASI-DAD cohort

    Research squarePreprint

  6. NT-proBNP is associated with mortality in humans (Clinically stable, asymptomatic hemodialysis patients; irrespective of galectin-3 levels) (Adjusted hazard ratios 2.58 and 1.93 versus the reference group).

    “Higher NT-proBNP levels were associated with increased all-cause mortality, irrespective of galectin-3 levels”

    HumansClinically stable, asymptomatic hemodialysis patients; irrespective of galectin-3 levelsover 10 yearsn = 173

    Long-Term Outcomes in Hemodialysis Patients According to Combined NT-proBNP and Galectin-3 Biomarker Profiles

    Journal of clinical medicine

  7. NT-proBNP is associated with mortality in humans (elderly inpatients with CAD combined with HF).

    “Age, albumin, and NT.proBNP were three features most associated with three-year mortality.”

    Humanselderly inpatients with CAD combined with HF3 yearsn = 987

    Machine learning-based prediction of three-year mortality in elderly inpatients with coronary artery disease combined with heart failure

    International journal of medical informatics

  8. NT-proBNP is linked with a higher risk of mortality in humans (hip fracture surgery, high vs low NT-proBNP) (adjusted HR 2.66 (95% CI 1.63-4.32)).

    “the adjusted hazard ratio for 2-year all-cause mortality was 1.51 (95% CI 0.91-2.50) for those in the moderate NT-proBNP group and 2.66 (95% CI 1.63-4.32) for those in the high NT-proBNP group”

    Humanship fracture surgery, high vs low NT-proBNP2-yearn = 2,595

    NT-proBNP With Postoperative Complications and 2-Year Mortality Among Hip Fracture Patients: An Observational Cohort Study

    Orthopaedic surgery

  9. NT-proBNP predicts mortality in humans (fully adjusted models) (HR 2.19, 95% CI 1.73-2.78).

    “In fully adjusted models, NT-proBNP (HR = 2.19; 95% CI, 1.73-2.78), hs-cTnT (HR = 2.30; 1.63-3.24)”

    Humansfully adjusted modelsn = 4,087

    Comparative prognostic value of nine cardiorenal biomarkers for mortality among adults with prediabetes and diabetes

    Diabetes, obesity & metabolism

  10. NT-proBNP predicts mortality in humans (preserved LVEF without valvular disease) (HR 1.52 [1.03-2.24]).

    “NT-proBNP predicted both all-cause (HR 1.52 [1.03-2.24]) and CV mortality (HR 2.16 [1.20-3.87]).”

    Humanspreserved LVEF without valvular disease5.1 ± 0.2 yearsn = 393

    Untangling the prognostic value of diastolic dysfunction, NT-proBNP, and frailty in older patients with preserved left ventricular ejection fraction without valvular disease

    BMC geriatrics

All 28

Heart failure

upin humans6mixedin humans1HR 3.3–3.78

7 studies
  1. NT-proBNP predicts heart failure in humans (diabetes with risk factors for HF, NT-proBNP-based screening arm) (84 of 168 (50%)).

    “Of the 168 (48%) with an elevated NT-proBNP, 84 (50%) were diagnosed with HF following echocardiography”

    Human trialdiabetes with risk factors for HF, NT-proBNP-based screening armn = 168

    The Addition of the AHA PREVENT Risk Model to NT-proBNP–Based Screening in Patients with Diabetes and Risk Factors for Heart Failure: An Exploratory Analysis of TARTAN-HF

    ADA Scientific Sessions 2026 abstract

  2. NT-proBNP is associated with heart failure in humans (HR per doubling, 1.90; 95% CI, 1.74 to 2.08).

    “serial NT-proBNP measurements were strongly associated with incident HF (HR per doubling, 1.90; 95% CI, 1.74 to 2.08)”

    Humansplasma23.4 yearsn = 8,486

    Associations of Serially Measured NT-proBNP With Incident Heart Failure With Reduced and Preserved Ejection Fraction

    Mayo Clinic proceedings

  3. NT-proBNP is associated with heart failure in humans with and without diabetes.

    “NPPB (N-terminal pro-BNP) was associated with HF in those with and without diabetes.”

    Humanswith and without diabetes

    Proteomic Signatures of Cardiac Dysfunction Among People With Diabetes: The Atherosclerosis Risk in Communities Study

    Circulation. Heart failure

  4. NT-proBNP predicts heart failure in humans (diabetes mellitus) (AUROC 0.569 to 0.685, p<0.001).

    “Adding NT-proBNP to 30-year PREVENT HF risk score substantially improved LTR prediction performance (AUROC for 30-year risk: 0.569 to 0.685, p<0.001).”

    Humansdiabetes mellitusn = 5,986

    Association of natriuretic peptide concentration with lifetime risk of heart failure in adults with diabetes mellitus: a pooled cohort analysis

    AHA Scientific Sessions 2025 abstract

  5. NT-proBNP is linked with a higher risk of heart failure in humans (diabetes mellitus) (48.7% vs 51.7% in CVD control).

    “At index age 55 y, the LTR estimate for the NT-proBNP >125 pg/mL category (48.7%) was comparable to the positive control group with prevalent CVD”

    Humansdiabetes mellitusn = 5,986

    Association of natriuretic peptide concentration with lifetime risk of heart failure in adults with diabetes mellitus: a pooled cohort analysis

    AHA Scientific Sessions 2025 abstract

  6. Heart failure is associated with NT-proBNP in hospitalized older adults with sarcopenia and heart failure.

    “NT-proBNP and cardiac remodeling indices (IVS and LVEDD) were highest in patients with both conditions.”

    Humansin hospitalized older adults with sarcopenia and heart failurebloodn = 598

    Muscle or Heart? Functional Impact of Sarcopenia and Heart Failure in Geriatric Inpatients

    Journal of clinical medicine

  7. NT-proBNP is linked with a higher risk of heart failure in humans with LVH and highest biomarker tertile vs low biomarker levels without LVH (HR: 3.78; 95% CI: 2.78 to 5.15).

    “Adjusted risk of HF (N = 643 events) was approximately 3.8-fold higher among participants with LVH and in the highest biomarker tertile, compared with those with low biomarker levels without LVH (NT-proBNP, hazard ratio [HR]: 3.78; 95% confidence interval [CI]: 2.78 to 5.15”

    Humanswith LVH and highest biomarker tertile vs low biomarker levels without LVH

    Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study)

    JACC. Heart failure

  8. NT-proBNP is linked with a higher risk of heart failure in humans (HR 3.3 (95 % CI 1.8-6.1)).

    “increased risk of incident heart failure [hazard ratio (HR) 3.3 (95 % confidence interval (CI) 1.8-6.1)]”

    Humans5-yearn = 560

    Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study

    Age (Dordrecht, Netherlands)

More on Heart failure

Frailty

upin humans6OR 1.69

6 studies
  1. NT-proBNP predicts frailty in humans (community-dwelling old-old older adults) (AUC 0.64; 95% CI 0.59-0.70; P<0.001).

    “NT-proBNP had modest discriminative ability for frailty (AUC 0.64; 95% CI 0.59-0.70; P<0.001)”

    Humanscommunity-dwelling old-old older adultsserum46.9% femalesn = 588

    Association Between Serum N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) Levels and Frailty in Community-Dwelling Old-Old Older Adults - SONIC Study

    Circulation reports

  2. NT-proBNP is associated with frailty in humans (community-dwelling old-old older adults) (OR 1.69; 95% CI 1.23-2.32; P=0.001).

    “Log-transformed NT-proBNP was significantly associated with frailty compared to robust (OR 1.69; 95% CI 1.23-2.32; P=0.001)”

    Humanscommunity-dwelling old-old older adultsserum46.9% femalesn = 588

    Association Between Serum N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) Levels and Frailty in Community-Dwelling Old-Old Older Adults - SONIC Study

    Circulation reports

  3. NT-proBNP is linked with a higher risk of frailty in humans (hospitalized patients with chronic heart failure) (incidence of frailty 68.75%).

    “Multivariable logistic regression analysis showed that age, self-care ability, nutritional risk, Kinesiophobia and NT-proBNP were risk factors for frailty”

    Humanshospitalized patients with chronic heart failuren = 256

    Status and influencing factors of frailty in hospitalized patients with chronic heart failure: A cross-sectional study

    Journal of clinical nursing

  4. Frailty is associated with NT-proBNP in patients with acute decompensated heart failure (r=0.316, p<0.001).

    “increased levels of the N-terminal pro-brain natriuretic peptide (NT-proBNP) (r= 0.316; p<0.001)”

    Humansin patients with acute decompensated heart failurebloodn = 101

    Decompensation of Heart Failure in "Fragile" Patients: Clinical Features and Approaches to Therapy

    Kardiologiia

  5. NT-proBNP is linked with a higher risk of frailty in humans (without known CVD at baseline, NT-proBNP ≥300 pg/ml vs. <300 pg/ml) (HR 2.61 (95% CI: 1.28-5.33, P = 0.008)).

    “(HRs) of 2.13 (95% confidence interval (CI): 1.130-4.01, P = 0.020) and 2.61 (95% CI: 1.28-5.33, P = 0.008), respectively.”

    Humanswithout known CVD at baseline, NT-proBNP ≥300 pg/ml vs. <300 pg/mlplasmamedian follow-up of 21.7 yearsn = 5,199

    Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study

    BMC geriatrics

  6. NT-proBNP predicts frailty in humans (acute heart failure) (AUC 0.62).

    “In the elderly group, NT-proBNP was significantly related to the presence of frailty”

    Humansacute heart failure

    Differences According to Age in the Diagnostic Performance of Cardiac Biomarkers to Predict Frailty in Patients with Acute Heart Failure

    Biomolecules

  7. Frailty is associated with NT-proBNP in heart failure patients (SMD 0.33, 95% CI 0.25-0.40).

    “NT-proBNP (k = 23; SMD: 0.33, 95%CI 0.25-0.40, I2 = 72%, P < 0.01)”

    Reviewin heart failure patients

    Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis

    Aging clinical and experimental research

Age

upin humans5

5 studies
  1. Age is associated with NT-proBNP in humans (female hospital employees) (ρ = 0.23, p = 0.015).

    “NT-proBNP exceeded 125 pg/ml in 11.7% and correlated with age (ρ = 0.23, p = 0.015).”

    Humansfemale hospital employeesfemales

    The hidden burden of cardiovascular risk in working women

    Wiener klinische Wochenschrift

  2. Age is associated with NT-proBNP in routine clinical practice.

    “NT-proBNP concentrations increased significantly across age groups irrespective of the presence of CVD”

    Humansin routine clinical practice

    Real-World Distribution of NT-proBNP and Its Association with Age and Cardiovascular Disease in an Iranian Tertiary Hospital

    Research SquarePreprint

  3. Age is associated with NT-proBNP in people living with HIV (aOR 1.10 per 1-year increase, 95% CI 1.04-1.15, p = 0.0004).

    “In multivariable analysis, older age was independently associated with elevated NT-proBNP (adjusted odds ratio [aOR] per 1-year increase: 1.10; 95% CI: 1.04-1.15; p = 0.0004)”

    Humansin people living with HIV

    Prevalence of Cardiovascular Disease Risk Factors and NT pro-BNP for Cardiovascular Disease Risk Prediction among Older People Living with HIV in Almaty, Kazakhstan

    Research squarePreprint

  4. Age is associated with NT-proBNP in humans.

    “NT-proBNP and cTnI were positively associated with increasing age.”

    Humans10 yearsn = 1,007

    Predictors of 10-year changes in levels of N-terminal pro B-type natriuretic peptide and cardiac troponin I in the elderly

    International journal of cardiology

  5. NT-proBNP is associated with age in humans.

    “An association between both BNP and Nt-proBNP concentrations and age was found.”

    Humans

    Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly

    Clinica chimica acta; international journal of clinical chemistry

Atrial fibrillation

upin humans4HR 1.37–2.35

4 studies
  1. NT-proBNP is linked with a higher risk of atrial fibrillation in adults with hypertension (HR 2.35, 95% CI 1.56-3.55).

    “elevated NT-proBNP were associated with incident AF (HR, 1.48 [95% CI, 1.07-2.05], 1.84 [95% CI, 1.30-2.60], and 2.35 [95% CI, 1.56-3.55]”

    Humansin adults with hypertensionmedian 3.76 yearsn = 7,261

    Cumulative Burden of Prediabetes, Subclinical Myocardial Injury, and Myocardial Stress and Risk of Incident Atrial Fibrillation in Adults With Hypertension

    medRxivPreprint

  2. Atrial fibrillation is associated with NT-proBNP in humans.

    “older age (80s and 90s), coronary artery disease, atrial fibrillation, and renal dysfunction were significantly associated with NT-proBNP ≥ 300 pg/mL”

    Humansn = 611

    Prevalence of high N-terminal prohormone of brain natriuretic peptide levels and associated factors among community-dwelling older adults aged over 75 years (The SONIC study): a cross-sectional study

    BMC research notes

  3. NT-proBNP is linked with a higher risk of atrial fibrillation in humans (RR=3.84, 95% CI 3.03 to 4.87).

    “Elevated NT-proBNP levels were associated with a higher risk of developing AF (top vs bottom quartile, RR=3.84, 95% CI 3.03 to 4.87”

    Humansn = 136,089

    Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies

    Heart (British Cardiac Society)

  4. NT-proBNP predicts atrial fibrillation in humans (HR 1.37, 95% CI 1.19-1.59).

    “A meta-analysis of NT-proBNP demonstrated its association with a higher incidence of AF (HR 1.37, 95%CI 1.19-1.59)”

    Review

    Identification of Biomarkers for Predicting New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis

    European journal of preventive cardiology

More on Atrial fibrillation

Cognitive decline

upin humans3HR 1.28

3 studies
  1. NT-proBNP is associated with cognitive decline in humans (without prior atrial fibrillation).

    “Elevated NT pro-BNP was significantly associated with the “dramatic decrease” trajectory.”

    Humanswithout prior atrial fibrillation8-year follow-upn = 4,486

    Markers of left atrial cardiopathy and cognitive function trajectories in adults aged ≥ 45 years without atrial fibrillation: a population-based study

    BMC neurology

  2. NT-proBNP predicts cognitive decline in humans (β = -0.12; 95%CI -0.23 to -0.01; p = 0.038).

    “with steeper decline evident in those with higher NT-proBNP (β = -0.12; 95%CI = -0.23 to -0.01; p = 0.038)”

    Humans5 years

    Associations between cognitive frailty and circulating cardiovascular biomarkers in a memory clinic cohort

    GeroScience

  3. NT-proBNP is associated with cognitive decline in humans (HR 1.28, 95% CI 1.18–1.39).

    “Elevated NT-proBNP and hs-cTnT independently predict dementia and cognitive decline”

    Review

    Cardiac Biomarkers as Predictors of Cognitive Decline and Incident Dementia: A Systematic Review and Meta-Analysis of the Heart-Brain Connection

    AHA Scientific Sessions 2026 abstract

Major adverse cardiovascular events

upin humans3

3 studies
  1. NT-proBNP is associated with major adverse cardiovascular events in humans (Type 2 diabetes; elevated versus non-elevated baseline NT-proBNP) (aHR 1.34, 95% CI 1.10-1.64).

    “Elevated (vs. non-elevated) NT-proBNP at baseline was associated with a higher risk of MACE (aHR 1.34, 95% CI 1.10-1.64)”

    HumansType 2 diabetes; elevated versus non-elevated baseline NT-proBNPMedian follow-up of 9.1 yearsn = 3,326

    Heart markers flagged risk, not benefit from tighter pressure control

    AHA Scientific Sessions 2026 abstract

  2. NT-proBNP predicts major adverse cardiovascular events in humans (adjusted HR per SD 1.50, 95% CI 1.36-1.65).

    “NT-proBNP showing the strongest association (adjusted HR per SD 1.50, 95% CI 1.36-1.65)”

    Humans4.5 yearsn = 10,433

    Circulating biomarkers and polygenic scores for cardiovascular risk prediction in healthy older adults: differential and complementary contributions

    Atherosclerosis

  3. NT-proBNP is associated with major adverse cardiovascular events in humans (Preoperative NT-proBNP >450 pg/mL; after osteoporotic hip fracture repair surgery).

    “only preoperative RBCT, creatinine >1 mg/dL and NT-proBNP >450 pg/mL remained as independent preoperative risks factors for postoperative MACE”

    HumansPreoperative NT-proBNP >450 pg/mL; after osteoporotic hip fracture repair surgery30 days after surgeryn = 140

    Risk factors for major adverse cardiovascular events after osteoporotic hip fracture repair surgery

    Injury

Cardiovascular mortality

upin humans3HR 1.87–2.16

3 studies
  1. NT-proBNP predicts cardiovascular mortality in humans (NT-proBNP greater than 125 pg/mL; adjusted for CKM stage, age, sex, and race/ethnicity) (Adjusted HR 1.87, 95% CI 1.61–2.17; p<0.001).

    “Elevated NT-proBNP independently predicted CVD mortality beyond CKM stage (adjusted HR=1.87, 95% CI 1.61-2.17, p<0.001).”

    HumansNT-proBNP greater than 125 pg/mL; adjusted for CKM stage, age, sex, and race/ethnicity16.9 years of follow-upn = 12,264

    Heart strain marker linked to cardiovascular death risk

    AHA Scientific Sessions 2026 abstract

  2. NT-proBNP predicts cardiovascular mortality in humans (preserved LVEF without valvular disease) (HR 2.16 [1.20-3.87]).

    “and CV mortality (HR 2.16 [1.20-3.87]).”

    Humanspreserved LVEF without valvular disease5.1 ± 0.2 yearsn = 393

    Untangling the prognostic value of diastolic dysfunction, NT-proBNP, and frailty in older patients with preserved left ventricular ejection fraction without valvular disease

    BMC geriatrics

  3. NT-proBNP predicts cardiovascular mortality in humans (symptoms associated with HF) (approximately 200 pmol/L).

    “Based on cardiovascular mortality, decision limits for BNP (approximately 50 pmol/L, approximately 170 ng/L) and Nt-proBNP ( approximately 200 pmol/L, approximately 1700 ng/L) (population II) were determined.”

    Humanssymptoms associated with HF6 yearsn = 474

    Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly

    Clinica chimica acta; international journal of clinical chemistry

SGLT2 inhibitors

downin humans3

3 studies
  1. SGLT2 inhibitors are associated with NT-proBNP in humans (hemodynamically stable patients with acute pulmonary embolism) (158 (96–443) vs. 1000 (333–3433) pg/mL; p < 0.001).

    “lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, [158 (96–443) vs. 1000 (333–3433), 95% CI (467–1153) pg/mL, p < 0.001]”

    Humanshemodynamically stable patients with acute pulmonary embolism

    Association between chronic sodium-glucose cotransporter 2 inhibitors use and right ventricular function in hemodynamically stable patients with acute pulmonary embolism

    Frontiers in cardiovascular medicine

  2. SGLT2 inhibitors are associated with NT-proBNP in humans (systemic right ventricle and heart failure) (31% reduction; adjusted geometric mean 796 to 550 ng/L; exp(β) 0.69, 95% CI 0.58–0.83).

    “the adjusted geometric mean NT-proBNP value decreased from 796 to 550 ng/L under SGLT2i, corresponding to a 31% reduction”

    Humanssystemic right ventricle and heart failure12 months after versus 12 months before initiation

    Clinical outcomes and safety of SGLT2 inhibitor therapy in patients with a systemic right ventricle and heart failure: a pre-post analysis from the ACHIEVE-SGLT2i registry

    ESC Congress 2026 abstract

  3. SGLT2 inhibitors are associated with NT-proBNP in humans (heart failure with preserved ejection fraction) (347 [134.8–524.8] vs. 257 [161.3–427.5] pg/mL).

    “N-terminal pro-brain natriuretic peptide levels decreased significantly”

    Humansheart failure with preserved ejection fraction3 months70% womensn = 50

    Early Changes in Left Atrial Mechanics During Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Heart Failure with Preserved Ejection Fraction

    Anatolian journal of cardiology

More on SGLT2 inhibitors

Cardiac rehabilitation

downin humans3

3 studies
  1. Cardiac rehabilitation is associated with NT-proBNP in humans (Myocardial infarction with systolic dysfunction) (2154 [1063.5-3796.5] pg/mL before Phase 2; 375.5 [195.75-624.5] pg/mL after Phase 2; 342.5 [170.25-661] pg/mL at one year).

    “NTproBNP levels decreased significantly from 2154 [1063.5-3796.5] pg/mL before Phase 2 to 375.5 [195.75-624.5] pg/mL after Phase 2”

    HumansMyocardial infarction with systolic dysfunctionOne year after myocardial infarction80.5% malessn = 87

    Heart failure therapy optimization in myocardial infarction patients with systolic dysfunction during Phase 2 and 3 Cardiac Rehabilitation

    ESC Congress 2026 abstract

  2. Cardiac rehabilitation is associated with NT-proBNP in humans (heart failure; available admission and discharge measurements) (2130 pg/mL (IQR 1060–3710) at admission; 1570 pg/mL (IQR 937–2770) at discharge where available).

    “where available, discharge values showed a lower trend (1570 pg/mL, IQR 937–2770)”

    Humansheart failure; available admission and discharge measurementsearly intensive inpatient

    Early intensive inpatient cardiac rehabilitation in heart failure: the CardioRehab Registry Experience

    ESC Congress 2026 abstract

  3. Cardiac rehabilitation is associated with NT-proBNP in humans (subset of patients with clinically stable heart failure with reduced ejection fraction).

    “Mean NT-proBNP decreased (p < 0.01).”

    Humanssubset of patients with clinically stable heart failure with reduced ejection fractioninpatient22.8-day inpatient stay

    Cardiac rehabilitation in patients with reduced left ventricular function in Germany: insights from the multicentre MEDIAN Heart Failure Registry

    Clinical research in cardiology : official journal of the German Cardiac Society

More on Cardiac rehabilitation

C-reactive protein

upin humans2

2 studies
  1. C-reactive protein is associated with NT-proBNP in humans (heart failure, 12-week titration with beta-blockers) (low-high +30 pg/ml vs high-low -8 pg/ml, P = 0.011).

    “NT-proBNP changes were significantly different between the four hs-CRP groups (P = 0.011).”

    Human trialheart failure, 12-week titration with beta-blockers12-weekn = 488

    Systemic inflammation and functional capacity in elderly heart failure patients

    Clinical research in cardiology : official journal of the German Cardiac Society

  2. C-reactive protein is associated with NT-proBNP in humans (baseline measurement).

    “Baseline CRP and IL-6 were significantly and positively associated with NT-proBNP.”

    Humansbaseline measurementmales

    Inflammatory markers and incident heart failure in older men: the role of NT-proBNP

    Biomarkers in medicine

More on C-reactive protein

Asleep pulse pressure

downin humans1

1 study
  1. NT-proBNP predicts asleep pulse pressure in humans (Higher baseline NT-proBNP; independent of treatment assignment and adherence).

    “Higher NT-proBNP was associated with reduction in asleep pulse pressure.”

    Human trialHigher baseline NT-proBNP; independent of treatment assignment and adherence6 months

    Cardiovascular and inflammatory proteomic signatures distinguish mandibular advancement device from CPAP therapy and predict blood pressure response in obstructive sleep apnea

    ESC Congress 2026 abstract

Low serum calcium

upin humans1

1 study
  1. Low serum calcium is associated with NT-proBNP in humans (lowest versus higher calcium quintile).

    “those with lower Ca2+ (Q1, mean 2.2 ± 0.1 mmol/L) presented more peripheral edema and higher NT-proBNP levels (P < 0.05).”

    Human triallowest versus higher calcium quintile

    Impact of Empagliflozin on Serum Calcium and Phosphate in Heart Failure

    Journal of cardiac failure

More on Low serum calcium

SVEP1

upin humans1

1 study
  1. SVEP1 is associated with NT-proBNP in humans (changes between high- and low-sodium diets) (R=0.80).

    “SVEP1 changes correlated strongly with NT-proBNP (R=0.80, P<0.001)”

    Human trialchanges between high- and low-sodium diets

    Dietary Sodium-Regulated Plasma SVEP1 and Inverse Salt Sensitivity

    Hypertension (Dallas, Tex. : 1979)

More on SVEP1

Peak oxygen consumption

downin humans1

1 study
  1. NT-proBNP is associated with peak oxygen consumption in humans (new-onset HFrEF) (β = -1.11 (95% CI: -2.15 to -0.06, p = 0.039)).

    “reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and body mass index (BMI) were associated with higher pVO2 (β = -1.11 [95% CI: -2.15 to -0.06, p = 0.039]”

    Human trialnew-onset HFrEF12 weeksn = 48

    Determinants of changes in peak oxygen consumption in patients with new-onset heart failure

    International journal of cardiology

All 147

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human cohorts associate higher NT-proBNP with mortality, frailty, sarcopenia and cardiovascular events. Trials in people with heart failure report NT-proBNP reductions with SGLT2 inhibitors, while a henagliflozin trial reports no change.

  2. Summary rewritten as its findings changed.

    As it read before

    In humans, NT-proBNP is associated with mortality and an increased risk of heart failure hospitalization. In male rats, aerobic treadmill training decreases cardiac NT-proBNP levels in both healthy and diabetic animals.

  3. Summary written from the findings.

Latest

Dec 2025: 10Jan 2026: 43Feb 2026: 36Mar 2026: 32Apr 2026: 11May 2026: 8Jun 2026: 18Jul 2026: 10Aug 2026: 21Sep 2026: 31Oct 2026: 105Nov 2026: 60385 papers in 12 months
bioRxiv

Loss of nuclear support proteins harms mouse hearts and arteries

Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.

Preprint: mouse studyMechanisms

See all 745 papers on NT-proBNP